Global Emergency Contraceptive Pills Market to Grow 1.93% by 2020 - Growing Sales of Generic Brands - Research and Markets

DUBLIN, August 15, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Emergency Contraceptive Pills Market 2016-2020" report to their offering.

The report forecasts the global EC pills market to grow at a CAGR of 1.93% during the period 2016-2020.

Growing sales of generic brands will be a key trend for the market growth. Generic EC pills are increasingly being sold at different drug stores. Compared with branded EC pills, the generic EC pills are less costly and available to all with no age limit. These factors have led to increased sales of generic brands. For instance, Teva Pharmaceuticals generates the majority of its revenue from its generic brand Plan B, rather than its original brand, which is usually sold through pharmacy counters and requires a prescription for women under the age of 17. Thus, vendors are trying to implement push marketing for increasing sales and directly contribute to the revenue of the market during the forecast period.

According to the report, rise in exploration of sexual fantasies will be a key driver for market growth. Globally, there has been an increase in the exploration of sexual fantasies. Sexual norms, behaviors, and attitudes are undergoing a transformation because of increased exposure to the internet, TV shows, and erotic literature. This has also paved the way for casual sex with multiple partners. The younger generation is embracing experimentation when it comes to sex and is aware of the protection required. This is driving the demand for EC pills in the markets as they are effective and reliable in preventing pregnancy. The shift in the attitude of consumers is evident because, despite the economic slowdown, there are new players as well as niche players in the market.

Further, the report states that doubts regarding effectiveness will be a major challenge for the market.

Key vendors:

• Allergan
• Lupin
• Mankind
• Piramal
• Teva

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Geographical segmentation

PART 07: Key leading countries

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

PART 15: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/scd9vv/global_emergency

Related Topics: Sexual and Reproductive Health Drugs

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com